α2AP regulates vascular alteration by inhibiting VEGF signaling in systemic sclerosis: the roles of α2AP in vascular dysfunction in systemic sclerosis
Open Access
- 3 February 2017
- journal article
- research article
- Published by Springer Nature in Arthritis Research & Therapy
- Vol. 19 (1) , 1-8
Abstract
Systemic sclerosis (SSc) is a connective tissues disease of unknown origin characterized by vascular damage and extensive fibrosis. Recently, we demonstrated that α2-antiplasmin (α2AP) is associated with the development of fibrosis in SSc. We herein investigate the roles of α2AP in vascular dysfunction in SSc. Vascular damage in mice was determined by the levels of blood vessels and blood flow. Vascular functions in vascular endothelial cells (ECs) were determined by the levels of tube formation, cell proliferation, and endothelial junction-associated protein (VE-cadherin and PECAM1) production. The administration of α2AP induced vascular damage in mice. Conversely, the α2AP neutralization improved vascular damage in a bleomycin-induced mouse model of SSc. Additionally, we showed that the SSc fibroblast-conditioned media induced the reduction of tube formation, cell proliferation, and endothelial junction-associated protein production in ECs, and that α2AP neutralization improved them. We also examined the mechanisms underlying the effects of α2AP on vascular alteration in SSc and found that α2AP attenuated vascular endothelial growth factor-induced tube formation, cell proliferation, and endothelial junction-associated protein production through the adipose triglyceride lipase/tyrosine phosphatase SHP2 axis in ECs. Our findings demonstrate that α2AP is associated with vascular alteration, and that the blocking of α2AP improves vascular dysfunction in SSc.Keywords
Funding Information
- Takeda Science Foundation
This publication has 22 references indexed in Scilit:
- The vitamin K–dependent anticoagulant factor, protein S, inhibits multiple VEGF-A–induced angiogenesis events in a Mer- and SHP2-dependent mannerBlood, 2012
- Cellular and molecular aspects of vascular dysfunction in systemic sclerosisNature Reviews Rheumatology, 2010
- α2-Antiplasmin Is Associated with the Progression of FibrosisThe American Journal of Pathology, 2010
- Plasma D-dimer concentration in patients with systemic sclerosisBritish Journal of Dermatology, 2007
- α2‐Antiplasmin is involved in the production of transforming growth factor β1 and fibrosisJournal of Thrombosis and Haemostasis, 2007
- Systemic sclerosis fibroblasts inhibit in vitro angiogenesis by MMP‐12‐dependent cleavage of the endothelial cell urokinase receptorThe Journal of Pathology, 2006
- Lack of α2‐antiplasmin improves cutaneous wound healing via over‐released vascular endothelial growth factor‐induced angiogenesis in wound lesionsJournal of Thrombosis and Haemostasis, 2006
- The Functions of Plasminogen in Cardiovascular DiseaseTrends in Cardiovascular Medicine, 2004
- The kidney is a major site of alpha(2)-antiplasmin production.Journal of Clinical Investigation, 1996
- Identification and Some Properties of a New Fast‐Reacting Plasmin Inhibitor in Human PlasmaEuropean Journal of Biochemistry, 1976